Sanofi: Berenberg raises its price target
(CercleFinance.com) - On Wednesday, Berenberg reiterated its Buy recommendation on Sanofi shares while raising its target price for the stock from E115 to E120.
Following an annual check-up of the pharmaceutical group, the analyst believes that several catalysts could support the laboratory's profitability.
These include the prospect of approval of fitusiran for hemophilia in the US on 28 March, and possible approval of Dupixent for urticaria in April.
The broker also mentions possible approvals for tolebrutinib in multiple sclerosis, Dupixent in bullous pemphigoid and rilzabrutinib in immune thrombocytopenia in H2.
Given the attractive valuation of the stock - which is trading at a P/E of 11.8x vs. 13.5x for the sector in Europe - good news on the product portfolio is not priced in, in Berenberg's view.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.
Following an annual check-up of the pharmaceutical group, the analyst believes that several catalysts could support the laboratory's profitability.
These include the prospect of approval of fitusiran for hemophilia in the US on 28 March, and possible approval of Dupixent for urticaria in April.
The broker also mentions possible approvals for tolebrutinib in multiple sclerosis, Dupixent in bullous pemphigoid and rilzabrutinib in immune thrombocytopenia in H2.
Given the attractive valuation of the stock - which is trading at a P/E of 11.8x vs. 13.5x for the sector in Europe - good news on the product portfolio is not priced in, in Berenberg's view.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.
The information and analyses published by Cercle Finance are intended solely as a decision-making aid for investors. Cercle Finance cannot be held responsible, directly or indirectly, for the use of information and analyses by readers. Uninformed investors are advised to consult a professional advisor before investing. This information does not constitute an invitation to sell or a solicitation to buy.